TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06953960: A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of the BCL-2 Inhibitor Surzetoclax (ABBV-453) Given as Monotherapy or in Combination With Antimyeloma Regimens in Subjects With Multiple Myeloma

Sponsor: AbbVie · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 325 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$7,971,810

Rescue Site Savings

+$5,262,180

Unlock Full NCT06953960 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06953960 Rescue Dossier →